News & Events

News

All categories

Earnings

Press Release

All years

2019

2018

2017

2016

2015

2014

Affimed Provides Regulatory Update on AFM11 Clinical Program

April 17, 2019

Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

April 1, 2019

Affimed Reports 2018 Financial Results and Operational Progress

March 27, 2019

Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

March 20, 2019

Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity

March 19, 2019

Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019

February 27, 2019

Affimed to Present at Upcoming Investor Conferences

February 21, 2019

Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 4, 2019

Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day

December 7, 2018

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

December 3, 2018

Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

November 28, 2018

Affimed to Present at the Jefferies 2018 London Healthcare Conference

November 8, 2018

Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

November 7, 2018

Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting

November 1, 2018

Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

October 31, 2018

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold

October 8, 2018

Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference

August 30, 2018

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

August 27, 2018

Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress

August 8, 2018

Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

August 3, 2018

1
2
3
4
5
6
7

Events

All

Scientific

Investors

18Jun

15-ICML International Conference on Malignant Lymphoma

June 18 - 22, 2019 (Lugano, Schweiz)

30Sep

NK2019

September 30 - October 3, 2019 (Luxembourg)

Webcasts
More events

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.